Nivalis Therapeutics

Nivalis Therapeutics is developing a novel disease-modifying therapy designed to protect intracellular GSNO (S-nitrosoglutathione), an endogenous molecule with cell signaling effects relevant to the pathophysiology of cystic fibrosis (CF).